Compounded vs. Brand-Name GLP-1s: What the Evidence Actually Shows

Brand-name Wegovy and Zepbound are FDA-approved products, the versions tested in the large STEP and SURMOUNT trials^1,2,3,4. Compounded semaglutide and tirzepatide use the same molecules but aren't FDA-approved, so the FDA doesn't check their safety, effectiveness or quality before they reach you⁵. Compounded versions cost far less.

If you've priced GLP-1 medication, you've seen the gap: brand-name Wegovy or Zepbound can run well into four figures a month before insurance, while compounded semaglutide and tirzepatide from a telehealth provider often start under $200. That difference is real, and the reasons behind it are widely misunderstood. This is a measured, sourced look at what actually separates the two — the approval status, the pharmacy framework, the shortage that created the compounding boom and then ended it, the safety trade-offs, and the money. Pricing figures throughout reflect the published pricing of the providers we track (last reviewed 2026).

What "FDA-approved brand-name" actually certifies

Brand-name GLP-1s are FDA-approved finished drug products. Wegovy (semaglutide 2.4 mg) is approved as an adjunct to diet and exercise for chronic weight management, and its FDA prescribing information spells out the approved doses, titration schedule, and safety warnings¹. Zepbound (tirzepatide) carries a parallel approval for the same indication². "FDA-approved" is a specific claim: this exact molecule, at this exact dose, made by this manufacturer under this process, was reviewed for safety, efficacy, and manufacturing quality before it reached patients. Notably, Wegovy and Zepbound are the weight-management brand names for the same molecules sold under different names for diabetes — see Ozempic vs. Wegovy, Mounjaro vs. Zepbound if the branding is confusing.

That approval also anchors the numbers people quote. The pivotal trials studied these approved products: in STEP-1, once-weekly semaglutide produced about 15% average body-weight loss over 68 weeks in adults with overweight or obesity³. In SURMOUNT-1, tirzepatide reached roughly the low-to-mid 20% range at its higher doses over 72 weeks⁴. When you buy the brand, you're buying the version that generated that evidence.

What "compounded" means — and the 503A vs 503B split

Compounded GLP-1s are prepared by licensed pharmacies rather than sold as approved finished products. Compounding is a legitimate, long-standing part of pharmacy practice, but the FDA is explicit that compounded drugs are not FDA-approved: the agency does not verify their safety, effectiveness, or quality before they reach patients⁵. That is the single most important fact in this whole comparison.

Two legal categories do the compounding. A 503A pharmacy compounds for an individual patient against a specific prescription — the traditional model. A 503B "outsourcing facility" registers with the FDA, follows tighter manufacturing standards (current good manufacturing practice), and can produce larger batches⁵. Neither one yields an FDA-approved product, but the oversight and scale differ, which is why the pharmacy behind your prescription matters. Our companion guide on whether compounded GLP-1 is legit and safe walks through how to vet a specific pharmacy.

The shortage that built the compounding boom — and its resolution

Here's the context most articles skip. Federal law lets compounders make copies of an approved drug when that drug is officially in shortage. Semaglutide and tirzepatide were both on the FDA shortage list during the 2022–2024 demand surge, and that window is what made large-scale compounded GLP-1 telehealth possible in the first place.

That window has now closed. The FDA has confirmed that the tirzepatide and semaglutide shortages are resolved and set deadlines after which 503A pharmacies and 503B outsourcing facilities may no longer compound copies of these drugs based on the shortage⁶. In practice, that reshapes the compounded market: broad "shortage-based" compounding of straight semaglutide and tirzepatide is winding down. Compounding can still occur in narrower, legitimate circumstances — for example, a documented clinical need for a formulation the brand doesn't make — but the era of shortage-driven mass compounding is ending, and any provider you consider should be transparent about the legal basis for what it dispenses.

FDA's 2026 proposal on 503B compounding (updated October 2026)

On May 1, 2026, the FDA published a notice proposing not to add semaglutide, tirzepatide or liraglutide to the "503B Bulks List," the list of bulk ingredients that 503B outsourcing facilities may compound from when there is a clinical need⁸. Under the law, an outsourcing facility can compound from a bulk ingredient only if it is on that list or if the drug is on the FDA's drug shortage list at the time⁸. The FDA wrote that shortages and backorders don't count as a "clinical need," and noted that FDA-approved tirzepatide products were not on the shortage list⁸. The comment period, first set to close June 30, 2026, was extended to July 30, 2026⁹.

It is still a proposal. As of October 2, 2026, the Federal Register shows no final decision. The FDA says it will publish a final determination after reviewing the comments, and that the final version may differ from the proposal⁸. The notice concerns 503B outsourcing facilities; 503A pharmacies, which compound for individual patients, work under a separate section of the law⁵. If your compounded medication comes from a 503B facility, ask your provider what it plans to do if the proposal becomes final.

Safety and quality: where the real differences are

Because compounded products aren't FDA-reviewed, the quality controls rest on the pharmacy and the prescriber rather than an approval of that exact product⁵. The most concrete risk the FDA has flagged isn't the molecule itself but the delivery. In a safety alert, the agency described dosing errors with compounded injectable semaglutide — patients and even clinicians miscalculating milligrams, milliliters, and "units," in some cases administering five to ten times the intended dose and ending up hospitalized⁷. Approved pens like Wegovy are engineered to prevent exactly that kind of error; multi-dose compounded vials shift more responsibility onto the user.

None of this means compounded medication is inherently unsafe — millions of doses have been dispensed by careful providers — but it does mean the guardrails are different. With brand-name, the standardization is built in. With compounded, you are trusting the sourcing, the labeling, and the instructions, so a provider's transparency about its pharmacy and its dosing guidance is not a nicety; it's the safety margin.

The cost gap, in real numbers

The price difference is the whole reason compounded took off. Across the telehealth providers we track, compounded semaglutide commonly runs about $90–$250 a month and compounded tirzepatide about $145–$350 a month (last reviewed 2026). Brand-name Wegovy and Zepbound list well above that before insurance, though manufacturer self-pay vial programs have narrowed the gap for cash patients.

For many people the deciding question is simply whether insurance covers the brand. If it does, the out-of-pocket difference can shrink to little, and the FDA-approval assurance comes along for free. If it doesn't — and coverage for anti-obesity medication is still patchy — a vetted compounded program has been the affordable path. Because a GLP-1 is usually a multi-year commitment (see choosing a provider for long-term use), it's the ongoing price, not a first-month teaser, that actually matters. You can line up each provider's semaglutide and tirzepatide pricing side by side in the comparison hub. Or jump straight to the best options if you're paying without insurance, matched by need rather than one flat list.

So which one actually fits you

Start with two honest questions: what's my monthly budget after any insurance, and how much does the FDA-approval assurance matter to me? If the brand is covered or affordable through a manufacturer program, and you want the exact product from the trials, brand-name is the cleaner, more standardized choice. If cost is the binding constraint and you're comfortable with a transparent, well-run compounding provider that's clear about its legal basis and its pharmacy, compounded can still be a reasonable fit — with the dosing caveats above taken seriously.

Whichever side you land on, match the molecule to your goal first (semaglutide vs tirzepatide) and consider the format (injections vs oral or sublingual), then pick the provider. Not sure where you fall? The 2-minute quiz asks about budget, medication, and how much the approval assurance matters, then reweights our honest Match Score to surface providers that fit. You can also weigh a low-cost pick like Found or a brand-capable platform in the alternatives to Ro view against the featured provider below.

One caveat on the compounded side, because everything above turns on being able to see a price. Some sellers publish figures you cannot act on. Lighter You is the extreme case among the providers we review — no price you can pin down: a $99 headline that matches none of its products, "starting at" figures with no dose or term behind them, two programs carrying no number whatsoever, and an intake form that asks for your contact details before it shows anything more. Compounded is only cheaper than brand if you can find out what it costs.